Pembrolizumab
- Generic Name
- Pembrolizumab
- Brand Names
- Keytruda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1374853-91-4
- Unique Ingredient Identifier
- DPT0O3T46P
- Background
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
- Indication
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
- Associated Conditions
- Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Advaxis, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02325557
- Locations
- 🇺🇸
Recruiting, Providence, Rhode Island, United States
🇺🇸Recrutiing, Philadelphia, Pennsylvania, United States
🇺🇸University of Colorado Health Sciences Center (UCHSC), Aurora, Colorado, United States
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02318901
- Locations
- 🇺🇸
Western Regional Medical Center/Cancer Treatment Center of America, Goodyear, Arizona, United States
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT02316002
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 32
- Registration Number
- NCT02313272
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 10
- Registration Number
- NCT02306850
- Locations
- 🇺🇸
Saint Louis University Hospital, Saint Louis, Missouri, United States
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Craig L Slingluff, Jr
- Target Recruit Count
- 68
- Registration Number
- NCT02305186
- Locations
- 🇺🇸
Hartford HealthCare, Hartford, Connecticut, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic Cancer Center, Phoenix, Arizona, United States
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 59
- Registration Number
- NCT02303990
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2020-09-29
- Target Recruit Count
- 144
- Registration Number
- NCT02301039
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02298959
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT02287428
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.